Floatz logo

Rhgm-Csf

Lymphoma

Ou Bai, MD/PHDPhase 4 / ApprovedActive
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
65/ 100

Competitive context

288 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Rhgm-Csf is also rated in:

Febrile NeutropeniaDormant
BB
Indicative ·
69 / 100
View asset →
breast cancerDormant
BB
Indicative ·
67 / 100
View asset →
Granulocyte Colony-Stimulating FactorDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →